James Chalmers to Administration, Inhalation
This is a "connection" page, showing publications James Chalmers has written about Administration, Inhalation.
Connection Strength
1.098
-
10 years since TORCH: shining a new light on the risks of inhaled corticosteroids in COPD. Eur Respir J. 2017 09; 50(3).
Score: 0.432
-
Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respir Res. 2018 04 11; 19(1):63.
Score: 0.112
-
POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% = FEV1 < 50% Predicted) COPD? Yes. Chest. 2018 04; 153(4):778-782.
Score: 0.111
-
RESPIRE: breathing new life into bronchiectasis. Eur Respir J. 2018 01; 51(1).
Score: 0.111
-
Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. NPJ Prim Care Respir Med. 2017 Jun 29; 27(1):43.
Score: 0.106
-
Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017 03 13; 27(1):18.
Score: 0.104
-
Budesonide and risk of pneumonia. Lancet. 2009 Dec 19; 374(9707):2050.
Score: 0.063
-
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir Med. 2019 03; 7(3):213-226.
Score: 0.030
-
Oral versus inhaled antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018 03 27; 3:CD012579.
Score: 0.028